Retatrutide & Cagrilintide Blend — Triple-Agonist + Amylin Weight-Management Blend
This fixed-combination blend pairs Retatrutide (LY-3437943), a GLP-1/GIP/glucagon triple receptor agonist, with Cagrilintide, a long-acting amylin analogue. It stacks four mechanistically distinct pathways into one research compound for advanced metabolic study.
Mechanism of Action
Retatrutide covers three incretin/glucagon pathways: GLP-1 and GIP receptor agonism (appetite suppression and glucose-dependent insulin response) plus glucagon receptor (GCGR) agonism, which is studied for increasing energy expenditure and fat oxidation. Cagrilintide adds a fourth, mechanistically independent amylin satiety pathway. Together they target appetite regulation and metabolic rate through non-overlapping receptors for potentially additive effect.
Available Formats
- 10mg
- 20mg
Reconstitution: Reconstitute with Bacteriostatic Water (BAC Water) for multi-use stability, or Sterile Water for single-use protocols. Store lyophilized vials refrigerated at 2–8°C, protected from light.
Key Research Areas
🔬 Obesity Research
Layered multi-pathway appetite suppression across four receptor systems.
⚡ Energy Expenditure & Fat Oxidation
The glucagon-receptor arm of retatrutide is studied for raising metabolic rate.
⚡ Glycemic Control
GLP-1/GIP-driven insulin response in metabolic models.
⚡ Satiety Signaling
Cagrilintide’s amylin contribution to satiety and gastric-emptying research.
FOR RESEARCH USE ONLY (RUO). This product is not a drug, food, or cosmetic and is not approved for human or veterinary use. All statements describe proposed or preclinical research findings only. Intended strictly for in vitro and laboratory research by qualified professionals. EhBuddy Peptides assumes no liability for misuse.














Reviews
There are no reviews yet.